肝细胞癌女性生存优势随年龄变化:一项多中心队列研究
基于中国12家三级医院33238例肝细胞癌患者中的4175例接受根治性肝切除或消融者,分析性别与年龄对癌症特异性生存的影响。女性生存优势见于45-54岁围绝经期(HR 0.77)并于55-59岁绝经早期达峰(HR 0.57),绝经前(<45岁)与绝经后期(≥60岁)未见。女性雌激素使用者癌症特异性生存优于未使用者(HR 0.74)。
要点
- 女性肝细胞癌生存优势呈年龄依赖模式,见于围绝经期及绝经早期。
- 45-54岁女性5年癌症特异性生存85.7% vs 男性70.6%(HR 0.77)。
- 55-59岁女性5年癌症特异性生存89.8% vs 男性73.5%(HR 0.57)。
核心结论
- 肝细胞癌女性生存优势取决于年龄,可能与年龄依赖的性别特异因素有关。
研究设计与样本
- 多中心队列研究,来自中国12家三级医院共33238例肝细胞癌患者。
- 分析其中4175例接受根治性意向肝切除或消融的患者,包括3321例男性和854例女性。
- 采用Cox回归和Kaplan-Meier法分析癌症特异性生存,并用两种倾向评分方法和多重中介分析减少混杂。
- 分析女性雌激素使用史与生存的关系,以探索雌激素这一随年龄变化的候选性别特异因素的作用。
主要发现
- 女性生存优势出现于45-54岁围绝经期(HR 0.77;5年癌症特异性生存85.7% vs 70.6%;P = .018)。
- 女性生存优势在55-59岁绝经早期达峰(HR 0.57;5年癌症特异性生存89.8% vs 73.5%;P = .015)。
- 绝经前(<45岁)和绝经后期(≥60岁)组未见女性生存优势。
- 消融或肝切除术后患者中均观察到一致的模式,倾向评分分析后结果持续存在。
- 混杂或中介效应仅占性别生存差异的19.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) has a higher incidence in males, but the association of sex with survival remains controversial. This study aimed to examine the effect of sex on HCC survival and its association with age. METHODS: Among 33,238 patients with HCC from 12 Chinese tertiary hospitals, 4175 patients who underwent curative-intent hepatectomy or ablation were analyzed. Cancer-specific survival (CSS) was analyzed using Cox regression and Kaplan-Meier methods. Two propensity score methods and multiple mediation analysis were applied to mitigate confounding. To explore the effect of estrogen, a candidate sex-specific factor that changes with age, female participants' history of estrogen use, and survival were analyzed. RESULTS: There were 3321 males and 854 females included. A sex-related disparity of CSS was present and showed a typical age-dependent pattern: a female survival advantage over males appeared at the perimenopausal age of 45 to 54 years (hazard risk [HR], 0.77; 5-year CSS, 85.7% vs 70.6%; P = .018), peaked at the early postmenopausal age of 55 to 59 years (HR, 0.57; 5-year CSS, 89.8% vs 73.5%; P = .015), and was not present in the premenopausal (<45 y) and late postmenopausal groups (≥60 y). Consistent patterns were observed in patients after either ablation or hepatectomy. These results were sustained with propensity score analyses. Confounding or mediation effects accounted for only 19.5% of sex survival disparity. Female estrogen users had significantly longer CSS than nonusers (HR, 0.74; 5-year CSS, 79.6% vs 72.5%; P = .038). CONCLUSIONS: A female survival advantage in HCC depends on age, and this may be associated with age-dependent, sex-specific factors.
引用
- Pang C, Li JM, Wang Z, et al. Age-Dependent Female Survival Advantage in Hepatocellular Carcinoma: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2023. PMID: 37659766. doi:10.1016/j.cgh.2023.07.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。